On July 7, Insilico Medicine fell 5.11% in regular trading, trading at HK$34.84/share, with turnover of HK$207 million. The stock has weakened for multiple consecutive sessions following the Takeda partnership announcement.

On July 2, the company announced a global strategic collaboration with Takeda Pharmaceutical valued at up to $600 million, including approximately $60 million in upfront and near-term milestone payments plus royalties on commercialized drugs. Despite opening over 10% higher on the announcement date, shares reversed sharply and have continued declining as investors booked profits on the news.

Adding to selling pressure, a HK$784 million block trade occurred pre-market on June 30 following the expiration of lock-up restrictions, with early-stage investors coordinating disposals. Meanwhile, fundamental concerns persist as the company reported a 34.48% year-over-year revenue decline and a net loss of $352 million, with market participants questioning whether large BD deal values can translate into near-term revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)